Fluicell AB (publ) (“Fluicell” or the “Company”) carries out a rights issue of units amounting to approximately SEK 30 million before issue costs (the “Rights Issue”). If all warrants issued in the Rights Issue are fully exercised, the Company may receive additional proceeds of up to approximately SEK 24.5 – 47.6 million before issue costs. The proceeds from the Rights Issue are primarily intended to accelerate the development of the Company’s drug candidate within the field of type 1 diabetes. Subscription commitments and guarantee undertakings amount to a total of approximately SEK 24.5 million, corresponding to approximately 81.7 percent of the Rights Issue. The subscription period for the Rights Issue runs from January 15 to January 29, 2024.
You can find Fluicell’s full press release here. On January 10, 2024, the Company announced that it had received additional guarantee undertakings through a so-called top guarantee. The press release regarding the top guarantee is available here.
Fluicell is an innovation-driven life science company developing products within regenerative medicine and human tissue-based screening models, based on the Company’s patented high-resolution 3D bioprinting technology. Fluicell’s primary focus is to develop tissue-based therapeutic products for severe diseases where adequate treatment options are currently lacking. The Company is currently engaged in product development in the following areas: tissue-based therapeutic products for the treatment of type 1 diabetes, as well as human tissue models for cardiac safety screening and kidney disease research.
The Company’s product pipeline consists of a pharmaceutical product for the treatment of type 1 diabetes and two human screening products for cardiac safety pharmacology and kidney disease. The product candidates are based on highly detailed bioprinted tissues, created using Fluicell’s tissue production platform Nexocyte, which is built on Biopixlar®, the Company’s high-resolution bioprinting technology. Additionally, Fluicell offers the following research technology platforms for biological and biomedical research and drug development: BioPen®, Biozone 6®, and Dynaflow® Resolve.
Fluicell’s flagship program in type 1 diabetes aims to develop a treatment solution that restores the body's normal function and ability to regulate blood sugar levels through a unique therapy concept based on bioprinted cell clusters. These clusters mimic the composition and function of human pancreatic islets (Langerhans islets) and have the capability to regulate both high and low blood sugar levels.
The primary objective of the Rights Issue is to accelerate the development of the Company’s drug candidate for type 1 diabetes. Additionally, investments will be made to advance the development of cardiac tissue models for drug screening and to scale up and further develop the Company’s tissue production platform.
Fluicell is a Gothenburg-based company that has commercialized a technology for processing and studying individual cells, primarily within drug development. Utilizing Fluicell’s high-resolution bioprinting technology, the Company is engaged in the development of tissue-based therapies and screening models. The Company’s main focus areas include tissue-based therapies for the treatment of type 1 diabetes and cardiac tissue models for drug screening. Fluicell’s existing product portfolio includes the Biopixlar® and Biopixlar® AER platforms for high-resolution bioprinting in both 2D and 3D, as well as research instruments such as BioPen®, Dynaflow® Resolve, and Biozone 6®, which enable researchers to study, manipulate, and measure drug effects on individual cells with unprecedented detail. More information is available at www.fluicell.com.
Corpura Fondkommission is acting as the financial advisor in connection with the Rights Issue.
For more information, visit www.corpura.se or contact:
Sebastian Balsom
Phone: +46(0)70-389 48 88
Email: sebastian.balsom@corpura.se
